Back to Journals » ImmunoTargets and Therapy
![](https://www.dovepress.com/cr_data/cache/journal_image/138/cope/thumb_100_1000_100.jpg)
ImmunoTargets and Therapy
ISSN: 2253-1556
![](https://www.dovepress.com/cr_data/cache/journal_image/138/thumb_215_215_100.jpg)
Editor-in-Chief: Professor Michael R Shurin
ImmunoTargets and Therapy is an international journal that aims to present and publish basic and clinical research on the aspects of immunology in health and disease. ImmunoTargets and Therapy is primarily focused on the immunological basis of disease and explores the evidence behind new and existing immunotherapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Articles:
- View all (181)
- Volume 13, 2024 (26)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Latest articles:
- 5 records -
Mapping Single-Cell Transcriptomes of Endometrium Reveals Potential Biomarkers in Endometrial Cancer
Xu G, Pan T, Li S, Guo J, Zhang Y, Xu Q, Chen R, Ma Y, Li Y
ImmunoTargets and Therapy 2024, 13:349-366
Published Date: 16 July 2024
A Case Report of Pathologically Complete Response of a Huge Lymph Node Metastasis of Colorectal Cancer After Treatment with Intratumoral Oncolytic Virus H101 and Capecitabine
Wang Y, Wang T, Zhang Y
ImmunoTargets and Therapy 2024, 13:343-348
Published Date: 4 July 2024
Mycobacterium tuberculosis Biofilms: Immune Responses, Role in TB Pathology, and Potential Treatment
Assefa M, Girmay G
ImmunoTargets and Therapy 2024, 13:335-342
Published Date: 3 July 2024
![Video](assets/img/article_icons/video.png)
Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/g6H8yg1fq1g/1.jpg)
Gauthier M, Pierson J, Moulin D, Mouginot M, Bourguignon V, Rhalloussi W, Vincourt JB, Dumas D, Bensoussan D, Chastagner P, Boura C, Decot V
ImmunoTargets and Therapy 2024, 13:319-333
Published Date: 26 June 2024
Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis
Xu K, Xiang C, Yu Z, Li J, Liu C
ImmunoTargets and Therapy 2024, 13:305-317
Published Date: 17 June 2024